Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Xenon Pharmaceuticals Inc. (XENE) had Normalized Income after Taxes of $-110.74M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-110.74M |
|
-- |
|
-- |
|
$123.16M |
|
$-123.16M |
|
$11.83M |
|
$-111.32M |
|
$-111.32M |
|
$-110.74M |
|
$-110.74M |
|
$-110.74M |
|
|
Normalized Income after Taxes |
$-110.74M |
$-123.16M |
|
$-122.60M |
|
99.61M |
|
99.61M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$945.87M |
|
$7.77M |
|
$349.90M |
|
$1.30B |
|
$45.01M |
|
-- |
|
$8.37M |
|
$53.38M |
|
$1.24B |
|
$1.24B |
|
$1.24B |
|
96.75M |
|
| Cash Flow Statement Financials | |
$-184.29M |
|
$-738.52M |
|
$843.04M |
|
$199.16M |
|
$119.53M |
|
$-79.64M |
|
$33.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-184.69M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.91% |
|
-8.91% |
|
-8.55% |
|
-8.91% |
|
$12.84 |
|
$-1.85 |
|
$-1.85 |
|